| First Author | Basiorka AA | Year | 2016 |
| Journal | Blood | Volume | 128 |
| Issue | 25 | Pages | 2960-2975 |
| PubMed ID | 27737891 | Mgi Jnum | J:238925 |
| Mgi Id | MGI:5824593 | Doi | 10.1182/blood-2016-07-730556 |
| Citation | Basiorka AA, et al. (2016) The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood 128(25):2960-2975 |
| abstractText | Despite genetic heterogeneity, myelodysplastic syndromes (MDSs) share features of cytological dysplasia and ineffective hematopoiesis. We report that a hallmark of MDSs is activation of the NLRP3 inflammasome, which drives clonal expansion and pyroptotic cell death. Independent of genotype, MDS hematopoietic stem and progenitor cells (HSPCs) overexpress inflammasome proteins and manifest activated NLRP3 complexes that direct activation of caspase-1, generation of interleukin-1beta (IL-1beta) and IL-18, and pyroptotic cell death. Mechanistically, pyroptosis is triggered by the alarmin S100A9 that is found in excess in MDS HSPCs and bone marrow plasma. Further, like somatic gene mutations, S100A9-induced signaling activates NADPH oxidase (NOX), increasing levels of reactive oxygen species (ROS) that initiate cation influx, cell swelling, and beta-catenin activation. Notably, knockdown of NLRP3 or caspase-1, neutralization of S100A9, and pharmacologic inhibition of NLRP3 or NOX suppress pyroptosis, ROS generation, and nuclear beta-catenin in MDSs and are sufficient to restore effective hematopoiesis. Thus, alarmins and founder gene mutations in MDSs license a common redox-sensitive inflammasome circuit, which suggests new avenues for therapeutic intervention. |
